Pharmaceutical competition enforcement targets four practices: pay-for-delay settlements paying generic rivals to stay out (Lundbeck, Servier, Actavis), excessive pricing of off-patent essential medicines (Aspen, Pfizer/Flynn), product hopping and regulatory gaming that blunts generic substitution, and pipeline overlaps in mergers. The sector generates more abuse and merger intervention per euro of turnover than any other, because patents, procurement and prescription rules make markets structurally narrow.
Pharmaceutical competition law sits at the collision of patent rights, public health budgets and antitrust — which is why it produces the field’s most distinctive doctrines. A patent settlement lawful in contract terms can be a cartel; a price a company is free to set can be an abuse; a merger with no current overlap can be blocked over a molecule in Phase II. This guide maps the enforcement landscape, opening the sector-enforcement pillar of our Global Competition & Antitrust hub.
What is a pay-for-delay settlement?
A patent dispute settlement in which the originator transfers value to the generic challenger in exchange for the generic staying off the market — treated as a restriction by object in the EU where the transfer has no explanation other than the delay, and analysed under the rule of reason in the US after Actavis.
Can a drug price be too high in law?
In the EU and Türkiye, yes: excessive pricing is an exploitative abuse, and the Commission and national authorities have pursued cases (Aspen, Pfizer/Flynn phenytoin) over off-patent medicines repriced many times over. The US has no equivalent doctrine.
Why are pharma mergers different?
Because competition happens in pipelines: authorities analyse overlapping development programmes years from market, and pipeline divestitures are routine — the loss of a future competitor is the harm, not current market share.
Why is the sector so heavily policed?
Because its structure suppresses ordinary competitive discipline. Patents create lawful temporary monopolies; prescription decoupling means the person choosing the product does not pay for it; reimbursement systems set prices administratively; and regulatory approval creates entry barriers that no amount of capital can shortcut. Where competition does arrive, it arrives suddenly and destructively — generic entry typically collapses prices by 80–90% within two years — which gives originators enormous incentives to delay it by any available means.
The European Commission’s 2009 pharmaceutical sector inquiry documented that toolkit systematically: patent thickets and divisional filings, defensive patenting, litigation used strategically, interventions before regulators, and settlements with value transfers. Everything enforced since has followed from that inventory, and Türkiye’s Rekabet Kurumu, the CMA, the FTC and national authorities across Europe have each built dockets on the same patterns. For companies, the practical implication is that pharma-specific conduct is assessed against a body of doctrine that does not exist in other industries — general competition training is insufficient.
How are pay-for-delay settlements treated?
As potential cartels. In Lundbeck (€93.8 million, upheld through to the Court of Justice in 2021) the Commission condemned agreements in which the originator paid generic companies substantial sums, bought their stock for destruction and secured their agreement to stay out of citalopram markets. Servier (perindopril) added an abuse dimension — acquiring the competing technology as well as settling — with the litigation running to 2024. The organising EU test asks whether the generic was a potential competitor (it need not have won the patent case) and whether the value transfer is explicable by anything other than the delay.
US law reached a similar destination differently. FTC v. Actavis (2013) rejected both per se legality and per se illegality, holding that large, unexplained reverse payments can violate the antitrust laws and must be assessed under the rule of reason — a framework that has generated a decade of litigation over what counts as a payment (cash, side deals, no-authorised-generic commitments) and how large is large. The compliance consequence is uniform across regimes: patent settlements between originators and challengers need competition review before signature, and the value flows must be documented against genuine litigation-risk economics rather than negotiated as a commercial package.
Lundbeck’s citalopram patents were expiring; several generic producers were preparing entry. Lundbeck concluded agreements paying them tens of millions, purchasing their stock and securing their absence from the market for the agreement’s duration. The Commission fined Lundbeck €93.8 million and the generics €52.2 million; the General Court and, in March 2021, the Court of Justice upheld the decisions, confirming that generics who could realistically have entered were potential competitors and that the agreements restricted competition by object. The judgment settled the EU framework: a settlement’s patent-law validity is irrelevant if the payment buys the delay.
When does drug pricing become an abuse?
When a dominant supplier charges prices bearing no reasonable relation to the economic value of the product — the United Brands test applied to medicines whose patents have expired but whose supply remains concentrated. The pattern in the leading cases is identical: a company acquires an old, off-patent essential medicine with no realistic alternative supplier, then raises the price by multiples.
In the UK, the CMA fined Pfizer and Flynn over phenytoin sodium capsules after price rises of up to 2,600%, and the case ran through appeal to a re-taken decision confirming abuse. The Commission’s Aspen case ended in 2021 with binding commitments cutting prices of six off-patent cancer medicines across Europe by roughly 73% — the first EU excessive-pricing commitments in pharma. National authorities in Italy, Denmark and elsewhere have pursued parallel cases. The practical rule for anyone acquiring legacy medicine portfolios: a repricing strategy on a product with no substitutes and no entry prospect is an abuse theory waiting for a regulator, and our abuse framework guide explains why the exploitative branch — dormant in the US — is very much alive in Europe and Türkiye.
What are product hopping and regulatory gaming?
Strategies that blunt generic substitution without any settlement. Product hopping switches patients to a reformulated version (extended release, new device, different salt) shortly before generic entry, so that automatic substitution rules — which match a generic to the exact reference product — no longer bite. The reformulation may be genuinely better; the competition question is whether the switch’s timing and marketing were designed to strand the generic rather than to serve patients.
Regulatory gaming covers misuse of the approval and IP systems: the Court of Justice’s AstraZeneca judgment (2012) confirmed abuse where a dominant firm gave misleading information to patent offices to obtain extended protection and deregistered market authorisations to block generic reliance on them. Related conduct includes disparagement campaigns against biosimilars (fined in France and Italy), refusing to supply reference samples generics need for bioequivalence testing, and vexatious litigation. All of it is judged against the special responsibility of dominance, and all of it is documented in internal launch-defence plans that regulators later read — which makes lifecycle-management projects a standing item for legal review.
How are pharma mergers reviewed?
Through pipelines and portfolios. Because tomorrow’s competition is visible today in clinical development, authorities analyse overlaps between marketed products and candidates in trials, and between two candidates neither of which has launched — the loss of a future rival being the harm. Remedies are correspondingly forward-looking: divestitures of development programmes, licensing of candidate molecules, and transfers of manufacturing and regulatory dossiers to a buyer capable of completing the work.
The frontier is the killer-acquisition theory, born in this sector: the empirical finding that a share of pharma acquisitions target overlapping pipeline projects that are then discontinued. Deal-value thresholds in Germany and Austria, Türkiye’s technology-undertaking exception and member-state call-in powers exist partly to catch small acquisitions of promising biotechs. Acquirers should therefore expect scrutiny disproportionate to the target’s revenue, and should prepare the pipeline-rationale documentation that shows why a programme is being kept, accelerated or stopped — as our review-process guide explains, the internal documents drive the theory of harm.
How does distribution work in pharma competition law?
As a distinctive and heavily litigated area. Originators supply wholesalers who may export to higher-priced member states — parallel trade the EU treats as a legitimate expression of the single market. Attempts to stop it through supply quotas, dual pricing or refusals have produced a long case line: the Court of Justice’s GlaxoSmithKline and Sot. Lélos judgments held that a dominant supplier may not refuse to meet ordinary orders in order to block exports, though it need not satisfy orders that are out of all proportion to normal local demand.
Türkiye’s Rekabet Kurumu has run parallel cases on supply refusals and quota systems in pharmaceutical distribution. For manufacturers, the practical line is that supply management must rest on objectively documented local-demand criteria applied consistently — not on the destination of the goods — and quota systems designed after export patterns emerge are read as what they are.
What should pharma compliance programs cover that generic ones do not?
Five sector-specific modules. Patent settlements: mandatory competition review before signature, with the value transfer justified against litigation-risk economics. Lifecycle management: legal review of switch strategies, with documentation discipline on how launch-defence plans are written. Regulatory conduct: rules on submissions to patent offices and medicines agencies, and on deregistration decisions, after AstraZeneca.
Supply and distribution: quota and allocation policies grounded in documented local demand, given the parallel-trade case line. Medical and commercial communications: disparagement of generics and biosimilars has been fined in several member states, so scientific claims about competing products need evidentiary support and legal sign-off. Companies running a generic corporate program without these five are unprotected where their actual risk lies.
Frequently Asked Questions
Are all patent settlements illegal?
No — settlements with no value transfer, or where the generic enters before patent expiry on agreed terms, are normal and lawful. The problem arises when the originator pays the challenger and the challenger stays out; the size and rationale of the transfer are the analytical core.
Does an authorised-generic commitment count as payment?
It can. US courts have treated no-authorised-generic promises as valuable consideration for Actavis purposes, and EU practice examines all forms of value transfer including distribution deals, licences and stock purchases at above-market prices.
Can a company be forced to lower prices?
Through excessive-pricing enforcement, effectively yes — the Aspen commitments cut prices by roughly 73% across Europe, and the CMA’s phenytoin case sought price reductions. It remains an exceptional remedy applied to entrenched positions with no realistic entry.
How does Türkiye enforce in pharma?
The Rekabet Kurumu has an active pharmaceutical docket covering distribution restrictions, supply refusals to wholesalers and exporters, and abuse in the supply chain, alongside merger review of pharma transactions with Turkish turnover. Pricing is separately regulated, which shapes the theories available.
Discover more from Kurums | Business Intelligence
Subscribe to get the latest posts sent to your email.
